Stock Track | Pharming Group N.V. Soars 8.93% on Strong Q3 Results and Raised FY25 Guidance

Stock Track11-13

Shares of Pharming Group N.V. (PHAR) experienced a significant surge during Wednesday's trading session, soaring 8.93% in response to the company's impressive third-quarter financial results and upward revision of its fiscal year 2025 sales guidance.

The biotechnology company, which focuses on developing protein replacement therapies and precision medicines, reported better-than-expected Q3 financials, catching the attention of investors. Adding to the positive sentiment, Pharming Group raised its FY25 sales guidance above market estimates, signaling strong confidence in its future performance and growth prospects.

This upbeat news has propelled Pharming Group's stock to outperform the broader market, with the surge reflecting investors' enthusiasm for the company's robust financial health and optimistic outlook. As the biotech sector continues to attract attention, Pharming Group's strong performance and raised guidance could potentially position it as a notable player in the industry.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1170588331?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 00:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170588331","market":"sg","top_or_hot":-1,"title":"Stock Track | Pharming Group N.V. Soars 8.93% on Strong Q3 Results and Raised FY25 Guidance","media":"Stock Track","content":"<p>Shares of Pharming Group N.V. (PHAR) experienced a significant surge during Wednesday's trading session, soaring 8.93% in response to the company's impressive third-quarter financial results and upward revision of its fiscal year 2025 sales guidance.</p>\n\n<p>The biotechnology company, which focuses on developing protein replacement therapies and precision medicines, reported better-than-expected Q3 financials, catching the attention of investors. Adding to the positive sentiment, Pharming Group raised its FY25 sales guidance above market estimates, signaling strong confidence in its future performance and growth prospects.</p>\n\n<p>This upbeat news has propelled Pharming Group's stock to outperform the broader market, with the surge reflecting investors' enthusiasm for the company's robust financial health and optimistic outlook. As the biotech sector continues to attract attention, Pharming Group's strong performance and raised guidance could potentially position it as a notable player in the industry.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Pharming Group N.V. Soars 8.93% on Strong Q3 Results and Raised FY25 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Pharming Group N.V. Soars 8.93% on Strong Q3 Results and Raised FY25 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-13 00:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Pharming Group N.V. (PHAR) experienced a significant surge during Wednesday's trading session, soaring 8.93% in response to the company's impressive third-quarter financial results and upward revision of its fiscal year 2025 sales guidance.</p>\n\n<p>The biotechnology company, which focuses on developing protein replacement therapies and precision medicines, reported better-than-expected Q3 financials, catching the attention of investors. Adding to the positive sentiment, Pharming Group raised its FY25 sales guidance above market estimates, signaling strong confidence in its future performance and growth prospects.</p>\n\n<p>This upbeat news has propelled Pharming Group's stock to outperform the broader market, with the surge reflecting investors' enthusiasm for the company's robust financial health and optimistic outlook. As the biotech sector continues to attract attention, Pharming Group's strong performance and raised guidance could potentially position it as a notable player in the industry.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PHAR","symbol_name":"Pharming Group N.V.","start_time":0,"source_url":"","article_id":"1170588331","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170588331","pubTimestamp":1762965738,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Pharming Group N.V. (PHAR) experienced a significant surge during Wednesday's trading session, soaring 8.93% in response to the company's impressive third-quarter financial results and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PHAR":"Pharming Group N.V."},"translate_title":"股票追踪|Pharming Group N.V.第三季度业绩强劲，上调25财年指引，股价飙升8.93%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHAR":1},"content_text":"Shares of Pharming Group N.V. (PHAR) experienced a significant surge during Wednesday's trading session, soaring 8.93% in response to the company's impressive third-quarter financial results and upward revision of its fiscal year 2025 sales guidance.\nThe biotechnology company, which focuses on developing protein replacement therapies and precision medicines, reported better-than-expected Q3 financials, catching the attention of investors. Adding to the positive sentiment, Pharming Group raised its FY25 sales guidance above market estimates, signaling strong confidence in its future performance and growth prospects.\nThis upbeat news has propelled Pharming Group's stock to outperform the broader market, with the surge reflecting investors' enthusiasm for the company's robust financial health and optimistic outlook. As the biotech sector continues to attract attention, Pharming Group's strong performance and raised guidance could potentially position it as a notable player in the industry.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1170588331","isCrawlerRequest":true}